Lineage Cell Therapeutics (LCTX) Tops Q2 EPS by 1c, beats revenue

Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $3.23 million versus the consensus estimate of $2.2 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• Palo Alto Networks (PANW) Tops Q4 EPS by 4c, Offers Guidance
• Morgan Stanley Downgrades Smith & Nephew PLC. (SN:LN) (SNN) to Equalweight